Isodiol $ISOL to Begin Exporting Flagship Product to Chilean Market

Isodiol(CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)

Isodiol International Inc., a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, is pleased to announce that the Company has officially initiated the approval process to begin exporting its flagship product, Isoderm to Chile.

“Earlier this year, Chile became the first country in Latin America to allow the sale of cannabis-based medicines in pharmacies. This gives the Company a unique advantage considering our distribution partner, FarmaUSA, has existing distribution channels that we will be able to immediately utilize. We are thrilled by the possibility of expanding Isodiol’s Latin American market initiative to provide Chilean patients with high quality CBD products. As the global market evolves, Isodiol has every intention to be at the forefront of product development and innovation.”

-Marcos Agramont, CEO of Isodiol

Chile legalized the use of medicinal marijuana in 2015 and is among a number of Latin American countries gradually loosening laws prohibiting the cultivation, distribution, and consumption of cannabis. Isodiol is one of the first companies to register a CBD product with the Chilean Health Department.

Isoderm Direct Effects Technology™ CBD Cream is the Company’s innovative new product that is applied directly to the back of the neck at the hairline for delivery of cannabinoids using direct nerve connections of skin to central nervous system, without blood flow requirements and restrictions of blood-brain barrier. The proprietary formulation delivers fast relief from neurologic, psychiatric and pain conditions, without concerns of systemic side effects and drug interactions commonly encountered with systemic neuro-active compounds.

The Company anticipates the introduction of additional products into the Chilean market including new non-cannabis derived CBD products.